On Mar. 16, 2020, Meridian Bioscience announced its increased commitment to the global fight against COVID-19 by making available zero cost samples of the company’s proprietary technologies to developers and manufacturers of molecular assays for COVID-19 detection.

By utilizing Meridian’s specialized enzyme formulations (Fast RT-qPCR Mix and Lyo-Ready 1-Step RT-qPCR Mix) it is Meridian’s hope that diagnostic companies around the world will be able to develop COVID-19 detection assays with greater sensitivity, faster run-times and formatted for high throughput testing. In order to help expedite such development, Meridian is pleased to provide from stock its specialized enzyme formulations to manufacturers of a COVID-19 molecular detection assay at no cost for the purpose of initial testing and evaluation. F

ollowing the successful development of a COVID-19 detection assay or kit, it is Meridian’s commitment to continue to manufacture and supply its propriety formulations at commercial scale in order to meet the global demand.